SANTA BARBARA, Calif., Oct. 18, 2017 /PRNewswire/ -- Goldman Sachs is recognizing DotLab and its CEO and Founder, Heather Bowerman, as one of the 100 Most Intriguing Entrepreneurs of 2017 at its Builders + Innovators Summit in Santa Barbara, California. Goldman Sachs selected Bowerman as one of 100 entrepreneurs from multiple industries to be honored at the two-day event.
DotLab has developed the first-ever diagnostic test for endometriosis, a chronic disease marked by infertility and pain that affects 1 in 10 women worldwide and carries a $78 billion cost. Today, the disease can only be diagnosed via laparoscopic surgery under general anesthesia, and the average timeframe from onset to diagnosis is ten years. "DotLab is committed to revolutionizing the standard of care for the 176 million women who suffer from endometriosis," said Bowerman. "Our goal is to help them live healthier, more productive, and happier lives." For her work in biomedical engineering, Bowerman was also named by the MIT Technology Review as one of the top 35 global innovators and as a World Technology Award Finalist for Health & Medicine.
"We are pleased to recognize Heather Bowerman as one of the most intriguing entrepreneurs of 2017," said David M. Solomon, President and Co-Chief Operating Officer at Goldman Sachs. "This is the sixth year that we've hosted the Builders + Innovators Summit where emerging business leaders gather to discuss their common interests in building prosperous organizations."
For more than 145 years, Goldman Sachs has been advising and financing entrepreneurs as they launch and grow their businesses. In addition to honoring 100 entrepreneurs, the Summit consists of general sessions and clinics led by Goldman Sachs experts, seasoned entrepreneurs, academics and business leaders as well as resident scholars.
DotLab is a San Francisco-based healthcare technology company. DotLab's first product, DotEndo, is a saliva test that replaces surgery for the diagnosis of endometriosis-- and after initial diagnosis, the test monitors disease progression, recurrence, and therapy response. The results of a prospective study on the biomarkers will be presented at the 2017 American Society of Reproductive Medicine Scientific Congress and Expo in San Antonio, TX. For more information, please visit www.dotlab.com.